An Ho Jung, Jo Heejoon, Jung Chan Kwon, Kang Jin Hyoung, Kim Min Sik, Sun Dong-Il, Cho Kwang Jae, Cho Jung-Hae, Won Hye Sung, Sun Der Sheng, Ko Yoon Ho
Division of Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Republic of Korea.
Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, United States.
Pathol Res Pract. 2017 Aug;213(8):949-955. doi: 10.1016/j.prp.2017.05.006. Epub 2017 May 31.
Excision repair cross complement group 1 (ERCC1) expression is a predictive biomarker for platinum-containing treatment in squamous cell carcinoma of head and neck (SCCHN). However, the prognostic significance after surgical resection is not well understood.
Oropharynx (n=143) or oral cavity (n=61) SCCHN patients undergoing surgery were included. ERCC1 protein expression and HPV status were assessed by ERCC1 and p16 immunohistochemistry.
The ERCC1, over-expressed in 66.7% of patients, was associated with oral cavity cancer (P<0.001), well differentiation (P=0.036), and HPV negativity (P<0.001). In TCGA database, ERCC1 mRNA upregulation was enriched in HPV-negative and oral cavity cancers, and associated with HRAS mutation (P<0.001). The prognostic role of ERCC1 was not different according to HPV status. High ERCC1 expression showed a trend toward poor prognosis in patients with an advanced stage (P=0.079) with marginal significance.
The ERCC1 expression was not prognostic in surgically resected oropharynx/oral cavity SCCHN, irrespective of HPV status. However, it could provide additional prognostic information for advanced stage patients.
切除修复交叉互补组1（ERCC1）表达是头颈部鳞状细胞癌（SCCHN）含铂治疗的预测生物标志物。然而，手术切除后的预后意义尚不清楚。
纳入接受手术的口咽（n = 143）或口腔（n = 61）SCCHN患者。通过ERCC1和p16免疫组织化学评估ERCC1蛋白表达和HPV状态。
66.7%的患者ERCC1过表达，其与口腔癌（P < 0.001）、高分化（P = 0.036）和HPV阴性（P < 0.001）相关。在TCGA数据库中，ERCC1 mRNA上调在HPV阴性和口腔癌中富集，并与HRAS突变相关（P < 0.001）。ERCC1的预后作用根据HPV状态无差异。高ERCC1表达在晚期患者中显示出预后不良的趋势（P = 0.079），具有边缘显著性。
无论HPV状态如何，ERCC1表达在手术切除的口咽/口腔SCCHN中无预后意义。然而，它可为晚期患者提供额外的预后信息。
